BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 12171902)

  • 1. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
    Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
    Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
    Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
    J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
    Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
    Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
    Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
    Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
    Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
    Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.
    Calabrò L; Fonsatti E; Altomonte M; Pezzani L; Colizzi F; Nanni P; Gattei V; Sigalotti L; Maio M
    J Cell Physiol; 2005 Feb; 202(2):474-7. PubMed ID: 15389591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.
    Ayyoub M; Taub RN; Keohan ML; Hesdorffer M; Metthez G; Memeo L; Mansukhani M; Hibshoosh H; Hesdorffer CS; Valmori D
    Cancer Immun; 2004 Aug; 4():7. PubMed ID: 15298487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
    Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
    J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
    Dubovsky JA; McNeel DG
    Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
    Karpf AR; Lasek AW; Ririe TO; Hanks AN; Grossman D; Jones DA
    Mol Pharmacol; 2004 Jan; 65(1):18-27. PubMed ID: 14722233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).
    Coral S; Sigalotti L; Gasparollo A; Cattarossi I; Visintin A; Cattelan A; Altomonte M; Maio M
    J Immunother; 1999 Jan; 22(1):16-24. PubMed ID: 9924695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications.
    Sigalotti L; Coral S; Altomonte M; Natali L; Gaudino G; Cacciotti P; Libener R; Colizzi F; Vianale G; Martini F; Tognon M; Jungbluth A; Cebon J; Maraskovsky E; Mutti L; Maio M
    Br J Cancer; 2002 Mar; 86(6):979-82. PubMed ID: 11953832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
    Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
    Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
    Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
    Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
    Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
    Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
    Coral S; Parisi G; Nicolay HJ; Colizzi F; Danielli R; Fratta E; Covre A; Taverna P; Sigalotti L; Maio M
    Cancer Immunol Immunother; 2013 Mar; 62(3):605-14. PubMed ID: 23138873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.